ID   BCaP-37
AC   CVCL_0164
SY   BCap-37; Bcap-37; BCaP 37; BCap 37; Bcap 37; BCAP37; Bcap37
DR   MCCL; MCC:0000056
DR   CCTCC; GDC0206
DR   ChEMBL-Cells; CHEMBL3308069
DR   ChEMBL-Targets; CHEMBL613842
DR   PubChem_Cell_line; CVCL_0164
DR   TOKU-E; 4153
DR   Wikidata; Q54795332
RX   CelloPub=CLPUB00522;
RX   PubMed=4017778;
RX   PubMed=24009699;
RX   PubMed=26116706;
RX   PubMed=26782109;
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a breast squamous cell carcinoma.
CC   Population: African American.
CC   Doubling time: 34.1 +- 2.3 hours (PubMed=26782109).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: N-glycan profiling.
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700009). It was one of the sources for the STR profile of this entry.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): CCRID; PubMed=26116706
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D12S391: 20,25
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D6S1043: 18,19
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   CelloPub=CLPUB00522;
RA   Chen C.-Y., Zhang J.-Q., Wang S.-X.;
RT   "Establishment of human breast cancer in vitro -- establishment of
RT   breast cancer cell line BCaP-37 and preliminary observation of its
RT   biological characteristics.";
RL   Beijing Da Xue Xue Bao Yi Xue Ban 15:161-165(1983).
//
RX   PubMed=4017778;
RA   Zhang J.-Q., Wang S.-X., Chen C.-Y., Lu P.;
RT   "Biologic and morphologic characteristics of the BCaP-37 human breast
RT   cancer cell line.";
RL   Zhonghua Wai Ke Za Zhi 23:241-243(1985).
//
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:E72704-E72704(2013).
//
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).
//
RX   PubMed=26782109; DOI=10.3892/or.2016.4566;
RA   Xu M.-J., Jiang D.-H., Shen J.-Y., Zheng H.-L., Fan W.-M.;
RT   "Distinct characterization of two vinorelbine-resistant breast cancer
RT   cell lines developed by different strategies.";
RL   Oncol. Rep. 35:2355-2363(2016).
//